These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30468800)

  • 1. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
    Tozbikian GH; Zynger DL
    Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
    Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
    Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
    Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
    Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
    Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
    Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
    Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
    Na K; Woo HY; DO SI; Kim SW
    In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined use of SOX10 and GATA3 in mammary carcinoma.
    Qazi MS; McGregor SM
    Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
    Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
    Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
    Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
    Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
    Bradt A; Jing X; Smola BS; Lew M
    Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of Sox10 labeling in metastatic breast carcinomas.
    Nelson ER; Sharma R; Argani P; Cimino-Mathews A
    Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression.
    Keske A; Shetty S; Weisman P; Yu Q; McGregor SM; Xu J
    Pathol Res Pract; 2023 Aug; 248():154628. PubMed ID: 37399589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
    Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
    Mod Pathol; 2024 Jul; 37(7):100517. PubMed ID: 38763422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of SOX10 and GATA3 in breast cancer and their significance].
    Liu JL; Chen DS; Cheng ZQ; Hu JT
    Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):536-541. PubMed ID: 35673726
    [No Abstract]   [Full Text] [Related]  

  • 18. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
    Sejben A; Vörös A; Golan A; Zombori T; Cserni G
    Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation.
    Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q
    Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics of the SOX10+ subset of HER2+ breast cancer.
    Weisman P; Yu Q; Xu J
    Ann Diagn Pathol; 2023 Apr; 63():152087. PubMed ID: 36669230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.